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Response to Method Errors or Unexplained Biological
Information?
To the Editor:
We thank Drs de Simone and Devereux1 for their comments
and their continued contributions to the subject of allometric
normalization of left ventricular mass (LVM). The authors
confirm the important residual relationship between height and
LVM/height2.7 in an independent cohort and present population-
attributable risk (PAR) estimates of LV hypertrophy (LVH)
defined by LVM/height2.7 and by LVM/height.1.7
These data are best interpreted in light of the definition and
usefulness of PAR estimates and the overcorrection induced by
normalizing LVM to height,2.7 resulting in the residual relation-
ship between height and LVM/height.2.7 PAR is the portion of
the incidence of a disease in the population that is due to the
exposure, representing the proportional reduction in average
disease risk that would be achieved by eliminating the exposure
from the population while distributions of other risk factors
remain unchanged (assuming the exposure is causal).2 In a
multi-factorial disease setting like cardiovascular disease, the
focus of interest is the risk associated with the modifiable
exposure while other risk factors (particularly nonmodifiable
factors such as height) are kept unchanged.2,3 Given the relation-
ship between height and LVM/height,2.7 PAR estimates for LVH
defined by LVM/height2.7 will not only reflect LVH-associated
risk but also height-related risk, whatever its mechanism may be.
This is problematic from the public health, biological, and
clinical perspectives. First, correlates of LVH from an epidemi-
ological perspective, or its etiologic determinants from a biolog-
ical perspective, cannot be confidently addressed unless con-
founding by height is eliminated. Similarly, since PAR estimates
for LVH defined by LVM/height2.7 cannot isolate LVH-related
risk, part of the risk related to height may be incorrectly
attributed to LVH (hence adversely influencing computations of
the attributable risk for LVH). The association between height
and cardiovascular risk may be mediated by multiple biological
mechanisms.4 The biology of LVH is equally complex. There-
fore, separating height from LVH is crucial to dissecting biolog-
ical mechanisms related to each; this separation is achieved by
normalization to height,1.7 but not height.2.7 Eliminating the
influence of height on PAR is also mandatory from an empirical
preventive perspective, because height is nonmodifiable; as such,
failure to eliminate its influence defeats the very purpose of PAR
as a public health measure. The problems with PAR estimates
influenced by nonmodifiable factors can be illustrated by an
extreme example, such as the PAR for cardiovascular disease
associated with a biological age 20 years: despite its unques-
tionable extremely high value as estimated with a formula, it is
meaningless regarding expected risk reductions by preventive
strategies. Even if we ignored these fundamental issues, the data
demonstrate that despite its artificial advantage from capturing
height-associated risk, normalization to height2.7 does not out-
perform normalization to height1.7. In Multiethnic Study of
Atherosclerosis (MESA), PAR for hard cardiovascular events for
LVH defined by LVM/height1.7 and LVM/height2.7 were 15%
and 14.6%, respectively, whereas PAR for death were 11.4% and
7.7%, respectively, if anything, favoring the unbiased normal-
ization approach. We also note that LVM/height,1.7 but not
LVM/height,2.7 significantly predicted mortality in this cohort.5
Drs de Simone and Devereux suggest that the substantial
method difference between their original reference populations
and the populations studied by our group is the age span. When
we purposefully omitted adjustment for gender in allometric
modeling in our study, we obtained approximately cubic powers,
yet on adjustment for gender, we demonstrated that the allomet-
ric power for body height is 1.7, statistically rejecting 2.7 with
99.9% confidence. Therefore, the main cause for different
results is the correction for the confounding effect of gender. Our
studied populations encompassed a wide age range of 5
decades which are the most relevant for LVH-associated mor-
bidity and mortality. We studied large cohorts and participants
from various ethnicities, allowing stratified analyses. For optimal
allometric models, the effect of body size on the physiological
measure needs to be isolated from confounders, such as gender,
ethnicity, and age. Therefore, the narrower age range within each
of our independently examined cohorts is an advantage, rather
than a disadvantage, for estimation purposes. It should be
emphasized that results were, however, highly consistent in the
younger Asklepios cohort and the older MESA cohort. Addition-
ally, we note that it is not advantageous to include children,
adolescents, and adults in the same analyses, given the profound
modifications of anatomic proportions, body composition, and
metabolic needs induced by growth and sexual maturation in
childhood and adolescence. Analyses of subjects from all ages
without careful exclusion of age*height interactions as determi-
nants of LVM may be misleading. By analyzing adults only, the
risk of confounding by these interactions is minimized.
Finally, whereas public health statistics are important, we
emphasize the equally important clinical implications of allomet-
ric normalization. Our study demonstrates the large, systematic
misclassification of individuals at the extremes of the population
distribution of body height when using LVM/height,2.7 due to the
overestimation of nonlinearity, resulting in overcorrection for
height in tall individuals and undercorrection in short individuals.
The magnitude of misclassification is large; furthermore, the
stakes of addressing the presence of LVH in individuals from the
clinical standpoint are high, considering the potential impact of
false reassurance or a false diagnosis. Therefore, based on
available data and various public health, statistical, biological,
and clinical considerations, we believe that normalization for
height1.7 should be strongly preferred over normalization for
height.2.7
Sources of Funding
This work was supported by Fonds voor Wetenschappelijk
Onderzoek Vlaanderen grant G.0.838.10. MESA is conducted/
supported by NHLBI in collaboration with MESA Investigators.
This manuscript was prepared using a limited-access dataset
obtained from NHLBI and does not necessarily reflect the
opinions or views of all MESA Investigators or NHLBI.
(Hypertension. 2011;57:e9-e10.)
© 2011 American Heart Association, Inc.
Hypertension is available at http://hyper.ahajournals.org DOI: 10.1161/HYPERTENSIONAHA.110.167361
e9
Disclosures
None.
Julio A. Chirinos
Division of Cardiology
University of Pennsylvania/Philadelphia VAMC
Philadelphia, PA
Thierry C. Gillebert
Department of Cardiovascular Diseases
Ghent University
Ghent, Belgium
Patrick Segers
Institute of Biomedical Technology
Ghent University
Ghent, Belgium
Marc L. De Buyzere
Department of Cardiovascular Diseases
Ghent University
Ghent, Belgium
Richard Kronmal
School of Public Health
University of Washington
Seattle, WA
Muhammad W. Raja
Department of Medicine
University of Pennsylvania
Philadelphia, PA
Dirk De Bacquer
Department of Public Health
Ghent University
Ghent, Belgium
Martin St. John-Sutton
Division of Cardiology
University of Pennsylvania
Philadelphia, PA
Ernst R. Rietzschel
Department of Cardiovascular Diseases and
Department of Public Health
Ghent University
Ghent, Belgium
References
1. de Simone G, Devereux RB. Method errors or unexplained biological
information? Hypertension. 56:e177–e178.
2. Rockhill B, Newman B, Weinberg C. Use and misuse of population
attributable fractions. Am J Public Health. 1998;88:15–19.
3. Graubard BI, Flegal KM, Williamson DF, Gail MH. Estimation of attrib-
utable number of deaths and standard errors from simple and complex
sampled cohorts. Stat Med. 2007;26:2639–2649.
4. Langenberg C, Marmot M. Commentary: disentangling the association
between short height and cardiovascular risk–genes or environment? Int J
Epidemiol. 2003;32:614–616.
5. Chirinos JA, Segers P, de Buyzere ML, Kronmal RA, Raja MW, De BD,
Claessens T, Gillebert TC, St John-Sutton M, Rietzschel ER. Left ventricular
mass: allometric scaling, normative values, effect of obesity, and prognostic
performance. Hypertension. 2010;56:91–98.
e10 Hypertension March 2011
